Talk:Gemtuzumab ozogamicin

This is the talk page for discussing improvements to the Gemtuzumab ozogamicin article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Gemtuzumab ozogamicin.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Thank you, Andrew, for writing up mylotarg. Perhaps some references, especially on the role in causing VOD, would improve the article. JFW | T@lk 13:25, 20 October 2005 (UTC)[reply]

Done! Andrew73 15:55, 20 October 2005 (UTC)[reply]

Resubmission in 2017

With results from the ALFA-0701 CT Pfizer are resubmitting (for marketing approval) to US FDA and EU.Feb 2017. Possibly for slightly different indication ? - Rod57 (talk) 14:17, 5 February 2017 (UTC)[reply]

Sept 2017 says "The new FDA approval is for a lower recommended dosage range and a different administration schedule than the previous approval, and includes uses alone or in combination with chemotherapy. Additionally, the new FDA approval is for a different patient population than before, including adults with newly diagnosed CD33-positive AML, as well as certain younger patients who had experienced a relapse or had not responded to initial treatment. " - Rod57 (talk) 16:18, 20 September 2017 (UTC)[reply]

Outside USA

Was it ever approved by the EU ? When was it approved by Japan ? any others ? Was it withdrawn from all markets at the same time in 2010 ? - Rod57 (talk) 14:29, 5 February 2017 (UTC)[reply]

What results on overall survival

Has any study reported on or even estimated overall survival with GO ? Perhaps the trial that was stopped early was designed to do this ? - Rod57 (talk) 14:43, 5 February 2017 (UTC)[reply]